Literature DB >> 23252909

Animal models of antimuscle-specific kinase myasthenia.

David P Richman1, Kayoko Nishi, Michael J Ferns, Joachim Schnier, Peter Pytel, Ricardo A Maselli, Mark A Agius.   

Abstract

Antimuscle-specific kinase (anti-MuSK) myasthenia (AMM) differs from antiacetylcholine receptor myasthenia gravis in exhibiting more focal muscle involvement (neck, shoulder, facial, and bulbar muscles) with wasting of the involved, primarily axial, muscles. AMM is not associated with thymic hyperplasia and responds poorly to anticholinesterase treatment. Animal models of AMM have been induced in rabbits, mice, and rats by immunization with purified xenogeneic MuSK ectodomain, and by passive transfer of large quantities of purified serum IgG from AMM patients into mice. The models have confirmed the pathogenic role of the MuSK antibodies in AMM and have demonstrated the involvement of both the presynaptic and postsynaptic components of the neuromuscular junction. The observations in this human disease and its animal models demonstrate the role of MuSK not only in the formation of this synapse but also in its maintenance.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23252909      PMCID: PMC3915870          DOI: 10.1111/j.1749-6632.2012.06782.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  74 in total

Review 1.  Safety factor at the neuromuscular junction.

Authors:  S J Wood; C R Slater
Journal:  Prog Neurobiol       Date:  2001-07       Impact factor: 11.685

2.  3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis.

Authors:  Shuuichi Mori; Masahiko Kishi; Sachiho Kubo; Takuyu Akiyoshi; Shigeru Yamada; Tsuyoshi Miyazaki; Tetsuro Konishi; Naoki Maruyama; Kazuhiro Shigemoto
Journal:  J Neuroimmunol       Date:  2012-03-11       Impact factor: 3.478

Review 3.  Animal models of myasthenia gravis.

Authors:  P Christadoss; M Poussin; C Deng
Journal:  Clin Immunol       Date:  2000-02       Impact factor: 3.969

4.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

5.  AchR-positive myasthenia gravis with MRI evidence of early muscle atrophy.

Authors:  Vasiliki Zouvelou; Michael Rentzos; Panagiotis Toulas; Ioannis Evdokimidis
Journal:  J Clin Neurosci       Date:  2012-02-15       Impact factor: 1.961

6.  Biglycan is an extracellular MuSK binding protein important for synapse stability.

Authors:  Alison R Amenta; Hilliary E Creely; Mary Lynn T Mercado; Hiroki Hagiwara; Beth A McKechnie; Beatrice E Lechner; Susana G Rossi; Qiang Wang; Rick T Owens; Emilio Marrero; Lin Mei; Werner Hoch; Marian F Young; David J McQuillan; Richard L Rotundo; Justin R Fallon
Journal:  J Neurosci       Date:  2012-02-15       Impact factor: 6.167

7.  Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.

Authors:  Rinse Klooster; Jaap J Plomp; Maartje G Huijbers; Erik H Niks; Kirsten R Straasheijm; Frank J Detmers; Pim W Hermans; Kevin Sleijpen; Aad Verrips; Mario Losen; Pilar Martinez-Martinez; Marc H De Baets; Silvère M van der Maarel; Jan J Verschuuren
Journal:  Brain       Date:  2012-03-06       Impact factor: 13.501

8.  Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.

Authors:  David P Richman; Kayoko Nishi; Stuart W Morell; Jolene Mi Chang; Michael J Ferns; Robert L Wollmann; Ricardo A Maselli; Joachim Schnier; Mark A Agius
Journal:  Arch Neurol       Date:  2011-12-12

9.  Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis.

Authors:  Shuuichi Mori; Shigeru Yamada; Sachiho Kubo; Jie Chen; Seiji Matsuda; Masachika Shudou; Naoki Maruyama; Kazuhiro Shigemoto
Journal:  J Neuroimmunol       Date:  2012-01-04       Impact factor: 3.478

10.  Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.

Authors:  Stuart Viegas; Leslie Jacobson; Patrick Waters; Judith Cossins; Saiju Jacob; M Isabel Leite; Richard Webster; Angela Vincent
Journal:  Exp Neurol       Date:  2012-02-03       Impact factor: 5.330

View more
  4 in total

1.  Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravis.

Authors:  Vishwendra Patel; Anne Oh; Antanina Voit; Lester G Sultatos; Gopal J Babu; Brenda A Wilson; Mengfei Ho; Joseph J McArdle
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

Review 2.  Muscle-Specific Kinase Myasthenia Gravis.

Authors:  Lucia S Borges; David P Richman
Journal:  Front Immunol       Date:  2020-05-08       Impact factor: 7.561

3.  The Myotonic Plot Thickens: Electrical Myotonia in Antimuscle-Specific Kinase Myasthenia Gravis.

Authors:  Marcus Magnussen; Ioannis Karakis; Taylor B Harrison
Journal:  Case Rep Neurol Med       Date:  2015-12-03

4.  Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.

Authors:  Masaharu Takamori
Journal:  Front Mol Neurosci       Date:  2020-05-28       Impact factor: 5.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.